CNBC’s Jim Cramer says money should flow from stocks with heavy exposure to Ukraine and China into domestic retailers with strong growth.» Read More
Feb 4- Ten big rival drug companies have formed a pact to cooperate on a government-backed effort to accelerate the discovery of new drugs, the Wall Street Journal reported.
Jan 29- After three years of seeing major drugs like Zyprexa for schizophrenia lose patent protection and wipe away billions of dollars in revenue, Eli Lilly and Co Chief Executive Officer John Lechleiter wants to change the game plan.
U.S. bonds pushed higher on Friday, after disappointing manufacturing data from both the U.S. and China revived the safe haven bid for Treasurys.
Jan 24- Bristol-Myers Squibb Co on Friday reported stronger-than-expected quarterly results, but its shares fell because of investors' jitters about the pace at which the company is developing a promising new combination of cancer drugs.
Friday's midday movers:
U.S. stock prices could continue to correct, but it's too soon to say whether this is the big one.
CNBC's Jim Cramer offers some simple advice on how to deal with the Wall Street selloff.
*Knocks back Teva's Nerventra and Novartis' serelaxin. LONDON, Jan 24- Europe's drugs regulator gave its backing on Friday for marketing approval to be granted for Bayer's pulmonary hypertension drug Adempas and for GlaxoSmithKline's diabetes medicine Eperzan.
U.S. stock index futures pointed to another steep loss on Friday, with European and Asian shares trading lower.
LONDON, Jan 24- GlaxoSmithKline said on Friday European regulators had given the green light to its once-weekly diabetes drug albiglutide, which it is marketing as Eperzan. Albiglutide belongs to the same class of injectable GLP-1 drugs as Victoza from Novo Nordisk, as well as Byetta and Bydureon from Bristol-Myers Squibb and AstraZeneca.
Jan 24- Bristol-Myers Squibb Co's quarterly sales and earnings beat Wall Street expectations, helped by cost cuts and growing sales of its treatments for cancer, blood clots and diabetes. The company on Friday said it earned $726 million, or 44 cents per share, in the fourth quarter.
As Bristol-Myers Squibb prepares to report its Q4 earnings on Friday, CNBC's Morgan Brennan and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss if now is the time to invest in the biotech.
With uncertainty rampant in the market, pros will be watching earnings very closely. Which results matter most to Cramer?
Jan 15- Merck& Co Inc's experimental blood clot-preventing drug vorapaxar should be approved to reduce the risk of further heart problems in people who have suffered a recent heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA is not bound to follow the advice of its advisory panels but typically does so.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
WASHINGTON, Jan 14- The U.S. Food and Drug Administration appears skeptical that data submitted by Johnson& Johnson proves its anticoagulant Xarelto is effective in reducing the risk of further heart problems in patients who have recently suffered a heart attack.
*Shares in AstraZeneca rise 2 percent. LONDON, Jan 14- AstraZeneca expects to return to growth faster than analysts currently predict after a wave of drug patent expiries, with 2017 revenue likely to be broadly in line with the 2013 level.
Jan 13- Lexicon Pharmaceuticals Inc said its chief executive would leave and it would cut its workforce by about 45 percent, as it moves its focus away from drug discovery to completing the studies of its drugs in late-stage development. The company said Arthur Sands, CEO since 1995 and a co-founder, intends to develop a succession plan with the board.
The "Fast Money" traders share their final trades of the day.
Jan 8- U.S. health regulators on Wednesday approved an AstraZeneca drug from a new class of medicines to treat type 2 diabetes after previously rejecting it over safety concerns. The medicine was co-developed by Bristol-Myers Squibb Co and AstraZeneca.